Nanopharmaceutics

What Nanopharmaceutics does

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable small-molecule drug products for cancer, central nervous system (CNS) disorders, diabetes, and infectious diseases. The company is headquartered in Alachua, Florida and operates as a wholly-owned subsidiary of TRON Group Inc. (OTC: TGRP). Its core technological platform is built on nanoparticle and fine-particle formulation expertise specifically designed to improve the absorption and stability of hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs. The pipeline consists of nine clinical-stage proprietary and partnered programs, including Triapine (a ribonucleotide reductase inhibitor and radiosensitizer for neuroendocrine tumors, glioblastoma, and cervical cancer), Ammonium Tetrathiomolybdate (an oral copper chelator for triple-negative breast cancer), Aza-TdCyd (a DNA hypomethylating agent), PRX-3140 and the NP-18 series (5-HT and sigma receptor modulators for Alzheimer's, PTSD, and diabetes), NanoBUP (an oral swallowed buprenorphine capsule for opioid use disorder), Ramoplanin (an oral glycolipodepsipeptide antibiotic for C. difficile infection), and NanoDOX (a topical doxycycline hydrogel for atopic dermatitis and skin infections).

The company is protected by an extensive patent estate covering composition-of-matter, formulation, and method-of-use claims across all major pipeline assets, and holds cGMP manufacturing capability through its affiliated Alchem Laboratories Corporation subsidiary. Its go-to-market approach is anchored in federally-funded clinical research: the majority of trials are sponsored by the National Cancer Institute through the Experimental Therapeutics Clinical Trials Network (ETCTN) and NRG Oncology under Cooperative Research and Development Agreements (CRADAs), with execution distributed through lead academic medical centers including Dartmouth, Ohio State, Northwestern, University of Miami, and Massachusetts General Hospital.

Revenue mechanics reflect a clinical-stage R&D model rather than commercial product sales. Funding is generated primarily through government contracts (NIH, DOD, BARDA), CRADA milestone payments, co-development agreements with academic and industry partners (including PrecisionLife for CNS biomarker analytics), and cGMP API supply arrangements. No products are currently approved or commercially marketed, no public pricing is disclosed, and revenue is not publicly reported. The company has stated that a large undisclosed portfolio of preclinical development candidates is also advancing.

Name

Nanopharmaceutics

Legal name

Nanopharmaceutics, Inc.

Website

https://nanopharmaceutics.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1–10 employees

Short description

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical subsidiary of TRON Group Inc. (OTC:TGRP) that develops oral, topical, and injectable nanoparticle-formulated drug candidates for cancer, CNS disorders, diabetes, and infectious diseases, advancing nine programs from Phase 1 through Phase 3 via NCI-sponsored trials and academic medical center partnerships.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Clinical-stage Oncology, CNS, Metabolic, and Infectious Disease Drug Development)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Nanotechnology (541713)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

akta.pro secondary industries

Crystallization, Particle Engineering & Micronization Services (HLAGAHAJ), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Clinical-stage pharmaceutical development
• Targeted cancer therapeutics
• Nanoparticle drug formulations
• CNS disorder drug development
• Infectious disease antibiotics

Headquarters

HQ city

Alachua

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Development Services: Revenue generated through development of proprietary drug candidates in partnership with government agencies (NCI, NIH) and academic medical centers. Clinical-stage products are advanced through various phases with co-development agreements and CRADAs (Cooperative Research and Development Agreements).
2. Drug Development Collaborations: Strategic partnerships with pharmaceutical companies and research institutions for co-development of drug candidates, generating milestone payments and potential royalty streams upon successful commercialization.
3. API Manufacturing (cGMP): Manufacturing of Active Pharmaceutical Ingredients under cGMP conditions (Type II DMF) for Triapine and Aza-TdCyd products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Nanopharmaceutics is a clinical-stage specialty pharmaceutical company that discovers and develops proprietary oral, topical, and injectable small molecule drug products targeting cancer, CNS disorders, diabetes, and infectious diseases. It applies nanoparticle and fine-particle formulation technologies to improve the absorption, bioavailability, and stability of hard-to-deliver BCS class II and IV compounds, and advances candidates through Phase 1–3 clinical trials in collaboration with the U.S. NCI, leading academic medical centers, and pharmaceutical partners. The company also operates cGMP Active Pharmaceutical Ingredient manufacturing through its affiliate Alchem Laboratories Corporation.

Product overview

Nanopharmaceutics is a clinical-stage specialty pharmaceutical company developing a portfolio of oral, topical, and injectable small molecule drug products. The company's product portfolio includes 9 clinical-stage programs targeting cancer (Triapine®, Ammonium Tetrathiomolybdate, Aza-TdCyd), CNS disorders (NanoBUP™, PRX-3140, NP-18-2, NP-18-3), diabetes (PRX-3140), and infectious diseases (Ramoplanin™, NanoDOX®). The company leverages nanoparticle and fine-particle formulation technologies to improve drug absorption and stability for hard-to-deliver BCS category II and IV compounds. The products span multiple therapeutic areas and development stages from Phase 1 through Phase 3 clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• Triapine: Ribonucleotide reductase inhibitor / radiosensitizer for cancer treatment, including neuroendocrine tumors (NET) and glioblastoma multiforme (GBM).
• NanoDOX
• Ramoplanin
• NanoBUP
• PRX-3140
• NP-18-2
• NP-18-3
• Ammonium Tetrathiomolybdate (ATTM)

Products and services

• Triapine Triapine is a synthetic heterocyclic carboxaldehyde thiosemicarbazone that inhibits the RRM2 subunit of ribonucleotide reductase, blocking conversion of ribonucleoside diphosphates to deoxyribonucleotides and thereby blocking DNA synthesis and repair in cancer cells. It is being developed as a radiosensitizer for neuroendocrine tumors (NET), glioblastoma multiforme (GBM), and cervical/vaginal cancers in collaboration with NCI-sponsored clinical trials at Ohio State, University of Miami, Northwestern, and NRG Oncology.
• Ammonium Tetrathiomolybdate (ATTM) ATTM is an oral copper chelator that lowers copper levels in the body and reprograms the tumor microenvironment to create a non-permissive environment for metastases. It is being developed as an anti-metastasis agent for triple-negative breast cancer (TNBC), forming a tripartite complex with copper and protein and cleared primarily via the liver into bile.
• Aza-TdCyd Aza-TdCyd is a nucleoside analog DNA hypomethylating agent that inhibits DNA methyltransferase I (DNMT1), leading to reactivation of silenced tumor suppressor genes. It is currently in a Phase 1 clinical trial with an undisclosed partner.
• NanoBUP NanoBUP is an innovative oral swallowed capsule formulation of buprenorphine developed as a replacement for sublingual buprenorphine for opioid use disorder (OUD) maintenance therapy. It produces similar bioavailability with a lower Cmax compared to sublingual formulations, potentially reducing craving and supporting improved weaning during maintenance therapy.
• PRX-3140 PRX-3140 is a selective partial agonist of the 5-HT4 receptor (Ki = 14.3 nM) and a ligand for Sigma-1 and Sigma-2 receptors (Ki = 10 nM and 36 nM respectively). It is being developed for Alzheimer's disease (where it stimulates acetylcholine release to improve cognition and memory) and for diabetes (where it modulates glucocorticoid insulin suppression and cortisol levels). It demonstrates high CNS penetration without significant distal GI motility.
• NP-18-2 NP-18-2 is an orally-bioavailable selective 5-HT1A full agonist and Sigma-1 receptor ligand being developed for CNS disorders. It demonstrates high potency (Ki = 5.1-17 nM) for 5-HT1A receptor binding.
• NP-18-3 NP-18-3 is an orally-bioavailable selective 5-HT2B antagonist and Sigma-1/Sigma-2 receptor ligand being developed for CNS disorders. It demonstrates high selectivity for the 5-HT2B receptor (Ki = 3.4 nM) with over 500-fold differences compared to other 5-HT receptor subtypes.
• Ramoplanin Ramoplanin is a glycolipodepsipeptide antibiotic being developed as an oral capsule for Clostridioides difficile infection (CDI) treatment. It demonstrates bactericidal activity against gram-positive bacteria including C. difficile, VRE, and MRSA via a novel sporicidal mechanism that targets the exosporium.
• NanoDOX NanoDOX 1% Doxycycline Monohydrate Hydrogel is a topical doxycycline formulation with anti-inflammatory and pro-healing properties that blocks tissue proteolytic activity via the PAR2 pathway. It is being developed for atopic dermatitis treatment, skin wound healing, and as an antibiotic therapy for bacterial infections, with ongoing Phase 2 trials at Massachusetts General Hospital (NCT05411484) and the University of Western Australia.

Quantifiable outcome

• Phase 1 NET study: ORR of 21.4% (50% improvement vs NETTER-1), median PFS of 38.0 months (10 month improvement vs NETTER-1)
• +2 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• The University of Western AustraliacoreStrategic or Co-development Partner · 9 May 2025Phase 2 clinical trial (RESETTER Study) testing NanoDOX hydrogel with oral doxycycline for treatment of male partners with genital mycoplasmas to restore fertility (ACTRN12624001180505). Principal Investigator: A/Prof. Matthew Payne.
• PrecisionLifecoreStrategic or Co-development Partner · 15 June 2023Strategic CNS drug development collaboration utilizing PrecisionLife's combinatorial analytics platform to identify genetic biomarkers for patient stratification across multiple CNS clinical trials. Option for exclusive rights to patient stratification biomarkers discovered through the platform.
• National Cancer Institute (NCI) / National Institutes of Health (NIH)coreStrategic or Co-development PartnerMultiple Cooperative Research and Development Agreements (CRADAs) for clinical development of Triapine in various cancer indications including neuroendocrine tumors, glioblastoma, cervical cancer, and triple-negative breast cancer. NCI sponsors and funds clinical trials through the Experimental Therapeutics Clinical Trials Network (ETCTN) and NRG Oncology.
• Dartmouth Hitchcock Medical Center / Dartmouth Cancer CentercoreStrategic or Co-development PartnerPhase 1b/2 clinical study of tetrathiomolybdate with capecitabine and pembrolizumab in triple-negative breast cancer patients (NCT06134375). Principal Investigator: Linda Vahdat, MD MBA, Chief of Medical Oncology.
• Northwestern University / Robert H. Lurie Comprehensive Cancer CentercoreStrategic or Co-development PartnerPhase 1 adaptive dose escalation study of oral Triapine in combination with temozolomide for recurrent glioblastoma (NCT06410248). Principal Investigator: Karan Dixit, MD. Funded by BrainUp.
• Massachusetts General HospitalcoreStrategic or Co-development PartnerPhase 2 clinical study investigating laser assisted drug delivery of NanoDOX for wound healing (NCT05411484). Principal Investigator: Dieter Manstein, MD.
• University of Miami / Sylvester Comprehensive Cancer CentercoreStrategic or Co-development PartnerPhase 1 study of Triapine in combination with 177Lu-Dotatate for neuroendocrine tumors (ETCTN 10388). Principal Investigator: Aman Chauhan, MD, Leader of Neuroendocrine Tumor Program.
• Ohio State University Comprehensive Cancer CentercoreStrategic or Co-development PartnerLead institution for NCI-sponsored Phase 2 randomized trial (NCT05724108) comparing Triapine plus Lutetium Lu 177 Dotatate vs standard therapy for metastatic neuroendocrine tumors.
• Alchem Laboratories CorporationcoreStrategic or Co-development PartnerAffiliate company and majority-owned subsidiary providing GMP manufacturing capabilities, assay development, and high throughput screening services. Alchem holds world-wide exclusive rights to various pharmaceutical patents and provides cGMP manufacturing for APIs.
• Cato Research (Allucent)minorImplementation/ SI/ Consulting PartnerContract research organization providing clinical development and regulatory affairs support services.
• Southern ResearchminorStrategic or Co-development PartnerContract research organization providing preclinical and clinical research services.
• Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (ICP)minorStrategic or Co-development PartnerClinical pharmacology research institute for drug development collaboration.
• Discovery Cure Institute, Inc. (DCI)minorStrategic or Co-development PartnerDiscovery and development institute for therapeutic candidates.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Nanobiotix: Clinical-stage nanoparticle therapeutics company developing radioenhancer and immuno-oncology products. Most directly comparable to Nanopharmaceutics in its use of nanoscale formulation as a core technology applied to oncology indications.
• Lipocine Therapeutics: Specialty pharmaceutical company focused on proprietary oral drug delivery and reformulation of BCS Class II/IV compounds. Comparable in its formulation-led approach to improving bioavailability of challenging molecules.
• Cartesian Therapeutics: Clinical-stage biotechnology company (formerly Selecta Biosciences) developing nanoparticle-based therapeutics for autoimmune disease and oncology. Comparable as a nanoparticle formulation platform company advancing multiple clinical assets.
• Axsome Therapeutics: Clinical-stage CNS specialty pharmaceutical company developing differentiated therapies for neurological disorders. Comparable to Nanopharmaceutics' CNS pipeline (PRX-3140, NP-18-2/3) in scale, stage, and therapeutic focus.
• Cassava Sciences: Clinical-stage CNS-focused biopharmaceutical company developing treatments for Alzheimer's disease. Comparable in targeting CNS indications with a small-cap clinical-stage profile and dependence on a single high-conviction asset.
• Acumen Pharmaceuticals: Clinical-stage CNS biopharmaceutical company developing treatments for early Alzheimer's disease. Comparable as another small-cap CNS-focused clinical company competing for similar investor and partnership capital.
• BioXcel Therapeutics: Clinical-stage biopharmaceutical company leveraging AI/repositioning to develop therapeutics in neuroscience and immuno-oncology. Comparable in its multi-asset clinical pipeline across CNS and oncology indications.

Emerging players

• Annovis Bio: Clinical-stage CNS specialty pharmaceutical company developing therapies for neurodegenerative diseases. Comparable as a smaller emerging CNS clinical company, though narrower in indication scope.

Broad incumbents

• Jazz Pharmaceuticals: Established specialty pharmaceutical company with a diversified CNS and oncology portfolio. Comparable as a broader incumbent in the same therapeutic categories but with multiple approved products and global commercialization scale.
• Azurity Pharmaceuticals: Specialty pharmaceutical company (formed via acquisition of Spectrum Pharmaceuticals) with a focus on differentiated reformulated products for underserved patient populations. Comparable as a broader specialty pharma incumbent with formulation expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nanopharmaceutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanopharmaceutics